Biogaia

BioGaia, a Swedish Pharmaceutical Preparation Manufacturing company, reported its total carbon emissions in 2025 as about 3,261,000 kg CO2e. This includes about 90,000 kg CO2e from Scope 1 (mobile combustion), approximately 35,000 kg CO2e from Scope 2 (market-based), and about 3,040,000 kg CO2e from Scope 3 emissions.

In 2024, BioGaia's total emissions were approximately 3,554,000 kg CO2e, with Scope 1 mobile combustion emissions at about 73,000 kg CO2e, Scope 2 market-based emissions at about 33,000 kg CO2e, and Scope 3 emissions around 3,204,000 kg CO2e.

Looking back to 2019, the base year for their targets, BioGaia's total emissions were approximately 2,684,000 kg CO2e. This comprised around 75,000 kg CO2e from Scope 1 (mobile combustion), about 69,000 kg CO2e from Scope 2 (market-based), and roughly 2,599,000 kg CO2e from Scope 3 emissions.

BioGaia has committed to ambitious climate action. The company aims to reduce its Scope 1 and 2 greenhouse gas emissions by 46% by 2030, using 2019 as the baseline year. This Science Based Target is in alignment with the goals of the Paris Agreement, aiming to limit global warming to 1.5°C. Furthermore, BioGaia is working towards reducing its Scope 1 and Scope 2 emissions to near zero by 2050, demonstrating a long-term commitment to decarbonisation. The company also commits to measuring and reducing its Scope 3 emissions. These targets have been approved by the Science Based Targets initiative (SBTi) for small and medium-sized enterprises (SMEs).